MedWatch

Coloplast to issue notes for EUR 3.5bn

The medtech firm has announced that it is establishing a program to sell senior unsecured notes for up to EUR 3.5bn, aiming to finance the acquisition of Atos Medical.

Photo: Coloplast / PR

Coloplast is on the hunt for capital, and has prepared for this by establishing a Euro Medium Term Note (EMTN) program, the company has announced in a notification.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs